Capricor Therapeutics announced that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration, FDA, scheduled for late March. In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls, CMC, plans for commercial launch, if approved which may enable opportunities to expedite the pathway to a Biologics License Application, BLA, submission. The Company has previously been granted Regenerative Medicine Advanced Therapy, RMAT, and orphan drug designations for the use of CAP-1002 in Duchenne muscular dystrophy, DMD, and these designations enable sponsors to work closely with the FDA and receive its guidance on potential expedited pathways for approval. “At this time, with our pivotal Phase 3, HOPE-3 trial fully enrolled in Cohort A and top-line data expected in the fourth quarter of this year, we believe that discussing our CMC plans for potential commercialization with the FDA will allow us the opportunity to bring CAP-1002 to patients in the most expeditious manner possible for patients in need,” said Linda Marban, Ph.D., Capricor’s chief executive officer. “At Capricor, we remain focused on getting to approval as quickly as possible and we look forward to providing more details after this meeting.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAPR:
- Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
- Is CAPR a Buy, Before Earnings?
- Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
- Capricor Therapeutics announces manufacturing scale-up of CAP-1002 production
- Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2